180 related articles for article (PubMed ID: 23564067)
1. Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype.
Gottschalk B; Klein A
Mol Cell Biochem; 2013 Jul; 379(1-2):213-27. PubMed ID: 23564067
[TBL] [Abstract][Full Text] [Related]
2. SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors.
Tzeng YJ; Zimmermann C; Guhl E; Berg B; Avantaggiati ML; Graessmann A
Oncogene; 1998 Apr; 16(16):2103-14. PubMed ID: 9572491
[TBL] [Abstract][Full Text] [Related]
3. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.
Jackson JG; Pant V; Li Q; Chang LL; Quintás-Cardama A; Garza D; Tavana O; Yang P; Manshouri T; Li Y; El-Naggar AK; Lozano G
Cancer Cell; 2012 Jun; 21(6):793-806. PubMed ID: 22698404
[TBL] [Abstract][Full Text] [Related]
4. Combination of doxorubicin and sulforaphane for reversing doxorubicin-resistant phenotype in mouse fibroblasts with p53Ser220 mutation.
Fimognari C; Lenzi M; Sciuscio D; Cantelli-Forti G; Hrelia P
Ann N Y Acad Sci; 2007 Jan; 1095():62-9. PubMed ID: 17404018
[TBL] [Abstract][Full Text] [Related]
5. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells.
Tsou SH; Hou MH; Hsu LC; Chen TM; Chen YH
Int J Mol Med; 2016 Jan; 37(1):233-42. PubMed ID: 26572087
[TBL] [Abstract][Full Text] [Related]
7. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
8. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
9. Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts.
Kim TH; Kim HS; Kang YJ; Yoon S; Lee J; Choi WS; Jung JH; Kim HS
Biochim Biophys Acta; 2015 Feb; 1850(2):401-10. PubMed ID: 25445714
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3.
Graessmann M; Berg B; Fuchs B; Klein A; Graessmann A
Oncogene; 2007 May; 26(20):2840-50. PubMed ID: 17160024
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site.
Ruiz de Almodóvar C; Ruiz-Ruiz C; Rodríguez A; Ortiz-Ferrón G; Redondo JM; López-Rivas A
J Biol Chem; 2004 Feb; 279(6):4093-101. PubMed ID: 14623878
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral expression of mature human neutrophil peptide-1 potentiates the therapeutic effect of doxorubicin in a mouse 4T1 breast cancer model.
Li D; Qin Q; Wang XY; Shi HS; Luo M; Guo FC; Wang W; Wang YS
Oncol Rep; 2014 Mar; 31(3):1287-95. PubMed ID: 24378474
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells.
Feng R; Dong L
Int J Clin Exp Pathol; 2015; 8(6):6107-16. PubMed ID: 26261488
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule.
Ghebeh H; Lehe C; Barhoush E; Al-Romaih K; Tulbah A; Al-Alwan M; Hendrayani SF; Manogaran P; Alaiya A; Al-Tweigeri T; Aboussekhra A; Dermime S
Breast Cancer Res; 2010; 12(4):R48. PubMed ID: 20626886
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax.
Kong W; Jiang X; Mercer WE
Cancer Biol Ther; 2009 Mar; 8(6):555-63. PubMed ID: 19242108
[TBL] [Abstract][Full Text] [Related]
17. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.
Zhou M; Gu L; Findley HW; Jiang R; Woods WG
Cancer Res; 2003 Oct; 63(19):6357-62. PubMed ID: 14559824
[TBL] [Abstract][Full Text] [Related]
18. Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression.
Kotchetkov R; Driever PH; Cinatl J; Michaelis M; Karaskova J; Blaheta R; Squire JA; Von Deimling A; Moog J; Cinatl J
Int J Oncol; 2005 Oct; 27(4):1029-37. PubMed ID: 16142320
[TBL] [Abstract][Full Text] [Related]
19. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.
Liang Y; Besch-Williford C; Benakanakere I; Hyder SM
Int J Oncol; 2007 Oct; 31(4):777-84. PubMed ID: 17786308
[TBL] [Abstract][Full Text] [Related]
20. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
Elmore LW; Di X; Dumur C; Holt SE; Gewirtz DA
Clin Cancer Res; 2005 Apr; 11(7):2637-43. PubMed ID: 15814644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]